Investors & Media

  • Webcast
    2018 Wells Fargo Healthcare Conference
    09/05/18 2:25 pm EDT
  • Webcast
    Morgan Stanley 16th Annual Global Healthcare Conference
    09/12/18 9:20 am EDT
  • Webcast
    Investor Day – More details to follow
    11/09/18

Company Profile

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan, Canada and Brazil for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen , an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Volanesorsen filings for marketing approval have been submitted in the U.S., EU and Canada. Inotersen is progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Aug. 29, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 2018 Wells Fargo Healthcare Conference on Wednesday, September
Toggle Summary Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA
CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced that they received a Complete Response Letter (CRL) from the Division of
Toggle Summary Ionis Reports Second Quarter 2018 Financial Results
Year-to-date revenues increased 15%, driven by increased SPINRAZA revenue TEGSEDI approved and on track to launch in the EU Positive FDA Advisory Committee vote recommending approval of WAYLIVRA Conference call and webcast today, August 7, 2018, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Aug.
Toggle Summary IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington's Disease
IONIS-HTT Rx is the first and only drug to demonstrate reduction of mutant huntingtin protein, the underlying cause of Huntington's disease, in patients Roche plans to initiate a pivotal study of IONIS-HTT Rx (RG6042) CARLSBAD, Calif. , Aug. 2, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright Nasdaq. Minimum 15 minutes delayed.

©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.